Export 21 results:
Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is U  [Clear All Filters]
2003
R. Nussenblatt, Li, Z., Robinson, R., Shames, R., Tang, M., Mailman, M., Thompson, D., Peterson, J., Sen, H., Al-Khatib, S., Ursea, R., Srivastava, S., Bamji, A., Sran, P., Waldmann, T., and Buggage, R., Daclizumab therapy in Uveitis patients: Preliminary safety and activity data for establishing parameters for subcutaneous administration for long term therapy, 2003.
R. B. Nussenblatt, Thompson, D. J. S., Li, Z., Chan, C. Chao, Peterson, J. S., Robinson, R. R., Shames, R. S., Nagarajan, S., Tang, M. Tao, Mailman, M., Velez, G., Roy, C., Levy-Clarke, G. A., Suhler, E. B., Djalilian, A., Sen, H. Nida, Al-Khatib, S., Ursea, R., Srivastava, S., Bamji, A., Mellow, S., Sran, P., Waldmann, T. A., and Buggage, R. R., Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration., J Autoimmun, vol. 21, no. 3, pp. 283-93, 2003.
R. B. Nussenblatt, Thompson, D. J. S., Li, Z., Peterson, J. S., Robinson, R. R., Shames, R. S., Nagarajan, S., Tang, M. T., Mailman, M., Velez, G., Roy, C., Levy-Clarke, G. A., Suhler, E. B., Djalilian, A., Sen, H. N., Al-Khatib, S., Ursea, R., Srivastava, S., Bamji, A., Mellow, S., Sran, P., and , Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration, J Autoimmun, vol. 21, pp. 283-293, 2003.
R. Buggage, Thompson, D., Sen, H., Al-Khatib, S., Srivastava, S., Ursea, R., Bamji, A., Waldmann, T., and Nussenblatt, R., A masked randomized study to investigate the safety and efficacy of Daclizumab for treatment of Ocular Behcet’s Disease, 2003.
S. Saxman, Vena, D., Nasim, G., Mosby, K., Abrams, J., Christian, M., Kaplan, R., and Ungerleider, R., A National Cancer Institute Pilot Study to Enhance Enrollment in Clinical Trials: The Expanded Participation Project (EPP), 2003.
C. Parnes, Guillermin, J., Habersang, R., Nicholes, P., Chawla, V., Kelly, T., Fishbein, J., McRae, P., Goessler, M., Gatti, A., Calcagno, J. A., Eki, C., Harris, K. A., Joyave, J., McFarland, K., Protter, P., Sullivan, M., Stanford, A., Lovett, N., Ortiz, M., Rojas, S., Cyrus, S., Cyrus, J., Cohen, S., Buchin, D., Riordan, L., Zuniga, M., Shah, R., Minard, C., Quintin, A., Douglas, G., van Houten, J., Freutner, S., Chartrand, S., Nowatzke, P., Romero, J., Rhodes, T., Benoit, M., Walter, E., Walker, L., DeBonnett, L., Cross, M., Free, T., Martin, S., Shank, K., Guedes, B., Atkinson, L. Ann, Halpin, G. J., Rouse, K., Hand, I., Geiss, D., Marshall, J. R., Burleson, L., Boland, J., Seybold, K., Hunter, V., Unfer, S., Schmucker, J., Gley, M., Marcus, M., Thompson, P., Milla, P., Young, C., Zanni, R., Zinno, V., Fetter-Zarzeka, A., Busey, A., Sokunbi, M. A., Airington, S., Richard, N., Muraligopal, V., Lewis, S., F Weber, T., Giordano, B. P., Linehan, D., Roach, J., Davis, R., Rzepka, A. A., Booth, T., Smeltzer, D., Walsh, J., Arispe, E., Rowley, R., Bolling, C., Botts, T., Haskett, K., Raby, D., Batiz, E., Gelfand, A., Farrell, L., Butler, S., Colby, L., Schochet, P., Bentler, J., Hirsch, D., Wilkinson, L., Aaronson, A., Bennett, E., Wingate, J., Quinn, D., Komendowski, K., Deckard, M., Frogel, M., Nerwen, C., Copenhaver, S., Prater, M., Wolsztein, J., Mackey, K., Benbow, M., Naranjo, M., Hensley, S., Hayes, C., Sadeghi, H., Lawson, S. May, McCall, M., Combs, K., Ledbetter, J., Sarnosky, K., Swafford, C., Speer, M., Barton, W. J., Mink, J. W., Lemm, D., Hudak, M., Case, E., Rowen, J., Fuentes, S., Pane, C., Richardson, L., Chavarria, C., Cassino, D., Ghaffari, K., Carroll, C., Lee, H., Guclu, L., Johnson, C., Blum, V., Boron, M. L., Sorrentino, M., Hirsch, R. L., Van Veldhuisen, P. C., and Smith, C., Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry., Pediatr Pulmonol, vol. 35, no. 6, pp. 484-9, 2003.
R. Buggage, Thompson, D., Sen, H., Al-Khatib, S., Srivastava, S., Ursea, R., Bamji, A., Waldmann, T., and Nussenblatt, R., A Study to investigate the Safety and Efficacy of Daclizumab to treat the ocular complications related to the Behcet’s disease, 2003.
R. B. Nussenblatt, Rao, N. A., Foster, C. S., Sen, H. N., Srivastava, S., Ursea, R., Li, Z., Thompson, D. J., Peterson, J. S., Robinson, R. R., Shames, R. S., and Buggage, R. R., Subcutaneously administered daclizumab (SC-DAC, humanized anti-IL-2 receptor antibody) therapy for uveitis, 2003.